Tolvaptan 7.5mg Tablets

Tolvaptan 7.5mg Tablets are a prescription medicine containing tolvaptan 7.5mg as the active ingredient and the generic equivalent of Samsca® 7.5mg, the lowest available strength of the reference brand product developed by Otsuka Pharmaceutical. Tolvaptan is a selective vasopressin V2 receptor antagonist — an aquaretic agent — that promotes the excretion of free water without significant electrolyte loss. The 7.5mg strength is used where dose reduction below the standard 15mg starting dose is required, whether due to tolerability, clinical response or physician-directed dose adjustment. Generic tolvaptan 7.5mg tablets are available internationally across the USA, UK, Australia, UAE, Germany, France, Russia, South Korea and worldwide.

---

Product Information

---

What Is Tolvaptan 7.5mg Used For?

Tolvaptan 7.5mg is used in the same clinical setting as tolvaptan 15mg — the treatment of clinically significant hyponatraemia — but represents the lowest available dose for situations where the standard 15mg starting dose requires reduction.

Hyponatraemia
Tolvaptan is indicated for clinically significant euvolaemic and hypervolaemic hyponatraemia associated with:

• Heart failure
• Hepatic cirrhosis
• Syndrome of inappropriate antidiuretic hormone secretion (SIADH)

When is 7.5mg used instead of 15mg?
The 7.5mg dose is used where:

• The prescribing physician determines that a dose lower than the standard 15mg starting dose is appropriate
• A patient requires dose reduction due to tolerability or adverse effects at the 15mg dose
• Clinical or pharmacokinetic factors warrant a lower starting or maintenance dose
• Local prescribing guidelines or specialist protocols specify a lower initiation dose

This strength is not a standalone initiation dose in most standard prescribing information — dose selection is always made by a specialist physician based on individual patient assessment, serum sodium levels and clinical tolerability.

United States: The standard Samsca® initiation dose per US labeling is 15mg. The 7.5mg tablet provides a tool for physicians managing patients who require dose reduction below 15mg.

United Kingdom / EU: Samsca® 7.5mg is available in the UK/EU to support dose flexibility in clinical practice, particularly for SIADH management where individual patient response varies.

Australia: Tolvaptan 7.5mg products are subject to TGA registration and ARTG listing. Confirm current PBS status and eligibility with your prescriber or pharmacist.

UAE / Gulf: Subject to UAE Ministry of Health registration. Consult a UAE-licensed physician for current tolvaptan 7.5mg UAE availability.

Germany: Tolvaptan 7,5mg Tabletten are available in Germany as Samsca® 7,5mg. All are prescription-only (rezeptpflichtig).

France: Tolvaptane 7,5mg is available in France as Samsca® 7,5mg, subject to HAS reimbursement and prescription requirements.

Russia: Толваптан 7,5 мг is available as Самска® 7,5 мг in Russia, requiring a valid prescription.

South Korea: 톨밥탄 7.5mg is registered for prescription use per MFDS-approved labeling.

Always follow the prescribing information applicable to your country and the guidance of your licensed specialist.

---

How Tolvaptan 7.5mg Works

Tolvaptan 7.5mg works through exactly the same mechanism as tolvaptan 15mg. It selectively blocks the vasopressin V2 receptor in the renal collecting duct, preventing vasopressin-stimulated water reabsorption. This promotes aquaresis — the excretion of electrolyte-free water — which gradually raises serum sodium concentration in hyponatraemic patients.

At the 7.5mg dose, the degree of aquaresis and sodium correction is lower than at 15mg, providing a more conservative rate of sodium correction for patients where a gentler response is clinically appropriate. This is particularly relevant given the risk of osmotic demyelination syndrome (ODS) from overly rapid serum sodium correction — a risk that applies at all tolvaptan doses.

---

Tolvaptan Dose Comparison — 7.5mg vs 15mg vs 30mg vs 60mg

Dose titration is managed exclusively by the treating physician in a hospital or specialist setting. Never self-adjust tolvaptan dose.

---

Generic Tolvaptan 7.5mg vs Samsca® 7.5mg

Samsca® 7.5mg is the originator brand containing tolvaptan 7.5mg. Generic tolvaptan 7.5mg tablets contain the same active ingredient at the same strength but may differ in inactive ingredients, tablet appearance, packaging and manufacturer. Consult your pharmacist or specialist before switching between branded and generic tolvaptan products.

---

Key Safety Information — Tolvaptan 7.5mg

All safety considerations applicable to tolvaptan 15mg apply equally to the 7.5mg strength. The lower dose does not eliminate these risks — it only reduces their magnitude in some respects.

Hepatotoxicity — Serious Liver Injury
Tolvaptan can cause serious and potentially fatal liver injury at any dose. Liver function tests must be performed before starting treatment and monitored during therapy. Tolvaptan must be discontinued immediately if signs of liver injury develop.

Signs requiring immediate medical attention:

• Unusual or persistent fatigue
• Loss of appetite or nausea
• Right upper abdominal pain
• Jaundice (yellowing of skin or whites of eyes)
• Dark or tea-coloured urine

Osmotic Demyelination Syndrome (ODS)
Even at the 7.5mg dose, serum sodium must be monitored to ensure correction does not exceed safe rates. The risk of ODS is present at all tolvaptan doses. Tolvaptan must be initiated in a hospital or clinical setting equipped to monitor and manage serum sodium.

Contraindications

• Urgent need to raise serum sodium acutely
• Inability to sense or respond to thirst
• Hypovolaemic hyponatraemia
• Concurrent use of strong CYP3A4 inhibitors
• Anuria
• Severe hepatic impairment (refer to local SPC for specific thresholds)
• Known hypersensitivity to tolvaptan or excipients

Fluid Access
Patients taking tolvaptan at any dose must have unrestricted access to water at all times. Fluid restriction during tolvaptan treatment is dangerous and can lead to severe dehydration and hypernatraemia.

Drug Interactions

• Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin) — contraindicated
• CYP3A4 inducers (rifampicin, carbamazepine, phenytoin) — reduce tolvaptan efficacy
• P-glycoprotein inhibitors — may increase tolvaptan exposure
• Loop diuretics — additive aquaretic effect
• Hypertonic saline — concurrent use not recommended

Always read the patient information leaflet and prescribing information applicable to your country.

---

Tolvaptan 7.5mg — Availability by Country

---

Frequently Asked Questions — Tolvaptan 7.5mg

What is Tolvaptan 7.5mg used for?
Tolvaptan 7.5mg is used in the treatment of clinically significant hyponatraemia associated with heart failure, hepatic cirrhosis and SIADH. It is the lowest available strength and is used where dose reduction below the standard 15mg starting dose is clinically required.

Is Tolvaptan 7.5mg the generic for Samsca® 7.5mg?
Yes. Samsca® 7.5mg is the originator brand. Generic tolvaptan 7.5mg tablets contain the same active ingredient and strength. Inactive ingredients, appearance and manufacturer may differ.

What is the difference between Tolvaptan 7.5mg and 15mg?
Tolvaptan 15mg is the standard starting dose for hyponatraemia in most prescribing guidelines. Tolvaptan 7.5mg is the lower strength used where dose reduction is clinically required — due to tolerability, adverse effects or physician-directed clinical decision. Dose selection is always made by the treating specialist.

Why must Tolvaptan 7.5mg be started in hospital?
All tolvaptan doses — including 7.5mg — must be initiated in a hospital or clinical setting because of the risk of osmotic demyelination syndrome from too-rapid serum sodium correction. Serum sodium must be monitored closely during the first 24 hours regardless of dose.

Can Tolvaptan 7.5mg cause liver damage?
Yes. Hepatotoxicity risk applies to all tolvaptan doses including 7.5mg. Liver function must be monitored before and during treatment. Discontinue immediately and seek medical attention if symptoms of liver injury develop.

Is Tolvaptan 7.5mg a diuretic?
Tolvaptan is an aquaretic rather than a conventional diuretic. It promotes free water excretion without significant sodium or potassium loss — the mechanism that makes it useful for treating hyponatraemia.

Can I buy Tolvaptan 7.5mg tablets online?
Tolvaptan 7.5mg is prescription-only in the USA, UK, Australia, UAE and most markets worldwide. Due to hepatotoxicity risk and sodium monitoring requirements, it must be initiated under direct specialist supervision.

What is the difference between Tolvaptan 7.5mg and Samsca® 7.5mg?
Samsca® 7.5mg is the originator brand. Generic tolvaptan 7.5mg contains the same active ingredient and strength but may differ in excipients, tablet appearance and manufacturer. Consult your pharmacist before switching products.

Is Tolvaptan 7.5mg available in the UAE?
Tolvaptan products are subject to UAE Ministry of Health registration. Availability of the specific 7.5mg strength depends on the registered product in-country. Consult a UAE-licensed physician or pharmacist.

Does Tolvaptan 7.5mg interact with grapefruit?
Yes. Grapefruit and grapefruit juice inhibit CYP3A4 and can significantly increase tolvaptan exposure at any dose including 7.5mg. Avoid grapefruit and grapefruit juice during tolvaptan treatment.

---

Medical Disclaimer

This information is provided for educational and commercial reference purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Tolvaptan 7.5mg is a prescription-only medicine with serious hepatotoxicity risk and strict monitoring requirements. All doses of tolvaptan must be initiated in a hospital setting with serum sodium monitoring. Always use according to the applicable prescribing information and the advice of a qualified healthcare professional licensed in your country.

Last Updated: September 25, 2026